These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21092177)

  • 1. A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France.
    Benchikh A; Savage C; Cronin A; Salama G; Villers A; Lilja H; Vickers A
    BMC Cancer; 2010 Nov; 10():635. PubMed ID: 21092177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    Cancer; 2010 Jun; 116(11):2612-20. PubMed ID: 20336781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
    Vickers AJ; Cronin AM; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Schröder FH; Lilja H
    Clin Cancer Res; 2010 Jun; 16(12):3232-9. PubMed ID: 20400522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
    Vickers A; Cronin A; Roobol M; Savage C; Peltola M; Pettersson K; Scardino PT; Schröder F; Lilja H
    J Clin Oncol; 2010 May; 28(15):2493-8. PubMed ID: 20421547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
    Braun K; Sjoberg DD; Vickers AJ; Lilja H; Bjartell AS
    Eur Urol; 2016 Mar; 69(3):505-11. PubMed ID: 25979570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
    Gupta A; Roobol MJ; Savage CJ; Peltola M; Pettersson K; Scardino PT; Vickers AJ; Schröder FH; Lilja H
    Br J Cancer; 2010 Aug; 103(5):708-14. PubMed ID: 20664589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.
    Carlsson S; Maschino A; Schröder F; Bangma C; Steyerberg EW; van der Kwast T; van Leenders G; Vickers A; Lilja H; Roobol MJ
    Eur Urol; 2013 Nov; 64(5):693-9. PubMed ID: 23683475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.
    Vickers AJ; Cronin AM; Aus G; Pihl CG; Becker C; Pettersson K; Scardino PT; Hugosson J; Lilja H
    BMC Med; 2008 Jul; 6():19. PubMed ID: 18611265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
    Nordström T; Vickers A; Assel M; Lilja H; Grönberg H; Eklund M
    Eur Urol; 2015 Jul; 68(1):139-46. PubMed ID: 25151013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
    Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
    Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study.
    Bryant RJ; Sjoberg DD; Vickers AJ; Robinson MC; Kumar R; Marsden L; Davis M; Scardino PT; Donovan J; Neal DE; Lilja H; Hamdy FC
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
    Vickers AJ; Gupta A; Savage CJ; Pettersson K; Dahlin A; Bjartell A; Manjer J; Scardino PT; Ulmert D; Lilja H
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):255-61. PubMed ID: 21148123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study.
    Grönberg H; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Lancet Oncol; 2015 Dec; 16(16):1667-76. PubMed ID: 26563502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.
    Sjoberg DD; Vickers AJ; Assel M; Dahlin A; Poon BY; Ulmert D; Lilja H
    Eur Urol; 2018 Jun; 73(6):941-948. PubMed ID: 29519548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
    Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
    Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
    Vickers AJ; Wolters T; Savage CJ; Cronin AM; O'Brien MF; Pettersson K; Roobol MJ; Aus G; Scardino PT; Hugosson J; Schröder FH; Lilja H
    Eur Urol; 2009 Nov; 56(5):753-60. PubMed ID: 19682790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
    Carlsson SV; Peltola MT; Sjoberg D; Schröder FH; Hugosson J; Pettersson K; Scardino PT; Vickers AJ; Lilja H; Roobol MJ
    BJU Int; 2013 Sep; 112(5):602-9. PubMed ID: 23448270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study.
    Lin DW; Newcomb LF; Brown MD; Sjoberg DD; Dong Y; Brooks JD; Carroll PR; Cooperberg M; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Zheng Y;
    Eur Urol; 2017 Sep; 72(3):448-454. PubMed ID: 27889277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI: The ProScreen Randomized Trial.
    Auvinen A; Tammela TLJ; Mirtti T; Lilja H; Tolonen T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Natunen K; Nevalainen J; Raitanen J; Ronkainen J; van der Kwast T; Riikonen J; Pétas A; Matikainen M; Taari K; Kilpeläinen T; Rannikko AS;
    JAMA; 2024 May; 331(17):1452-1459. PubMed ID: 38581254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.